Cargando…

A Novel Network Pharmacology Strategy to Decode Metabolic Biomarkers and Targets Interactions for Depression

Depression is one of the most prevalent and serious mental disorders with a worldwide significant health burden. Metabolic abnormalities and disorders in patients with depression have attracted great research attention. Thirty-six metabolic biomarkers of clinical plasma metabolomics were detected by...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yao, Xu, Teng, Zhao, Ying-Xia, Ling-Hu, Ting, Liu, Shao-Bo, Tian, Jun-Sheng, Qin, Xue-Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373779/
https://www.ncbi.nlm.nih.gov/pubmed/32760300
http://dx.doi.org/10.3389/fpsyt.2020.00667
_version_ 1783561560170430464
author Gao, Yao
Xu, Teng
Zhao, Ying-Xia
Ling-Hu, Ting
Liu, Shao-Bo
Tian, Jun-Sheng
Qin, Xue-Mei
author_facet Gao, Yao
Xu, Teng
Zhao, Ying-Xia
Ling-Hu, Ting
Liu, Shao-Bo
Tian, Jun-Sheng
Qin, Xue-Mei
author_sort Gao, Yao
collection PubMed
description Depression is one of the most prevalent and serious mental disorders with a worldwide significant health burden. Metabolic abnormalities and disorders in patients with depression have attracted great research attention. Thirty-six metabolic biomarkers of clinical plasma metabolomics were detected by platform technologies, including gas chromatography–mass spectrometry (GC–MS), liquid chromatography–mass spectrometry (LC–MS) and proton nuclear magnetic resonance ((1)H-NMR), combined with multivariate data analysis techniques in previous work. The principal objective of this study was to provide valuable information for the pathogenesis of depression by comprehensive analysis of 36 metabolic biomarkers in the plasma of depressed patients. The relationship between biomarkers and enzymes were collected from the HMDB database. Then the metabolic biomarkers-enzymes interactions (MEI) network was performed and analyzed to identify hub metabolic biomarkers and enzymes. In addition, the docking score-weighted multiple pharmacology index (DSWMP) was used to assess the important pathways of hub metabolic biomarkers involved. Finally, validated these pathways by published literature. The results show that stearic acid, phytosphingosine, glycine, glutamine and phospholipids were important metabolic biomarkers. Hydrolase, transferase and acyltransferase involve the largest number of metabolic biomarkers. Nine metabolite targets (TP53, IL1B, TNF, PTEN, HLA-DRB1, MTOR, HRAS, INS and PIK3CA) of potential drug proteins for treating depression are widely involved in the nervous system, immune system and endocrine system. Seven important pathways, such as PI3K-Akt signaling pathway and mTOR signaling pathway, are closely related to the pathology mechanisms of depression. The application of important biomarkers and pathways in clinical practice may help to improve the diagnosis of depression and the evaluation of antidepressant effect, which provides important clues for the study of metabolic characteristics of depression.
format Online
Article
Text
id pubmed-7373779
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-73737792020-08-04 A Novel Network Pharmacology Strategy to Decode Metabolic Biomarkers and Targets Interactions for Depression Gao, Yao Xu, Teng Zhao, Ying-Xia Ling-Hu, Ting Liu, Shao-Bo Tian, Jun-Sheng Qin, Xue-Mei Front Psychiatry Psychiatry Depression is one of the most prevalent and serious mental disorders with a worldwide significant health burden. Metabolic abnormalities and disorders in patients with depression have attracted great research attention. Thirty-six metabolic biomarkers of clinical plasma metabolomics were detected by platform technologies, including gas chromatography–mass spectrometry (GC–MS), liquid chromatography–mass spectrometry (LC–MS) and proton nuclear magnetic resonance ((1)H-NMR), combined with multivariate data analysis techniques in previous work. The principal objective of this study was to provide valuable information for the pathogenesis of depression by comprehensive analysis of 36 metabolic biomarkers in the plasma of depressed patients. The relationship between biomarkers and enzymes were collected from the HMDB database. Then the metabolic biomarkers-enzymes interactions (MEI) network was performed and analyzed to identify hub metabolic biomarkers and enzymes. In addition, the docking score-weighted multiple pharmacology index (DSWMP) was used to assess the important pathways of hub metabolic biomarkers involved. Finally, validated these pathways by published literature. The results show that stearic acid, phytosphingosine, glycine, glutamine and phospholipids were important metabolic biomarkers. Hydrolase, transferase and acyltransferase involve the largest number of metabolic biomarkers. Nine metabolite targets (TP53, IL1B, TNF, PTEN, HLA-DRB1, MTOR, HRAS, INS and PIK3CA) of potential drug proteins for treating depression are widely involved in the nervous system, immune system and endocrine system. Seven important pathways, such as PI3K-Akt signaling pathway and mTOR signaling pathway, are closely related to the pathology mechanisms of depression. The application of important biomarkers and pathways in clinical practice may help to improve the diagnosis of depression and the evaluation of antidepressant effect, which provides important clues for the study of metabolic characteristics of depression. Frontiers Media S.A. 2020-07-15 /pmc/articles/PMC7373779/ /pubmed/32760300 http://dx.doi.org/10.3389/fpsyt.2020.00667 Text en Copyright © 2020 Gao, Xu, Zhao, Ling-Hu, Liu, Tian and Qin http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Gao, Yao
Xu, Teng
Zhao, Ying-Xia
Ling-Hu, Ting
Liu, Shao-Bo
Tian, Jun-Sheng
Qin, Xue-Mei
A Novel Network Pharmacology Strategy to Decode Metabolic Biomarkers and Targets Interactions for Depression
title A Novel Network Pharmacology Strategy to Decode Metabolic Biomarkers and Targets Interactions for Depression
title_full A Novel Network Pharmacology Strategy to Decode Metabolic Biomarkers and Targets Interactions for Depression
title_fullStr A Novel Network Pharmacology Strategy to Decode Metabolic Biomarkers and Targets Interactions for Depression
title_full_unstemmed A Novel Network Pharmacology Strategy to Decode Metabolic Biomarkers and Targets Interactions for Depression
title_short A Novel Network Pharmacology Strategy to Decode Metabolic Biomarkers and Targets Interactions for Depression
title_sort novel network pharmacology strategy to decode metabolic biomarkers and targets interactions for depression
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373779/
https://www.ncbi.nlm.nih.gov/pubmed/32760300
http://dx.doi.org/10.3389/fpsyt.2020.00667
work_keys_str_mv AT gaoyao anovelnetworkpharmacologystrategytodecodemetabolicbiomarkersandtargetsinteractionsfordepression
AT xuteng anovelnetworkpharmacologystrategytodecodemetabolicbiomarkersandtargetsinteractionsfordepression
AT zhaoyingxia anovelnetworkpharmacologystrategytodecodemetabolicbiomarkersandtargetsinteractionsfordepression
AT linghuting anovelnetworkpharmacologystrategytodecodemetabolicbiomarkersandtargetsinteractionsfordepression
AT liushaobo anovelnetworkpharmacologystrategytodecodemetabolicbiomarkersandtargetsinteractionsfordepression
AT tianjunsheng anovelnetworkpharmacologystrategytodecodemetabolicbiomarkersandtargetsinteractionsfordepression
AT qinxuemei anovelnetworkpharmacologystrategytodecodemetabolicbiomarkersandtargetsinteractionsfordepression
AT gaoyao novelnetworkpharmacologystrategytodecodemetabolicbiomarkersandtargetsinteractionsfordepression
AT xuteng novelnetworkpharmacologystrategytodecodemetabolicbiomarkersandtargetsinteractionsfordepression
AT zhaoyingxia novelnetworkpharmacologystrategytodecodemetabolicbiomarkersandtargetsinteractionsfordepression
AT linghuting novelnetworkpharmacologystrategytodecodemetabolicbiomarkersandtargetsinteractionsfordepression
AT liushaobo novelnetworkpharmacologystrategytodecodemetabolicbiomarkersandtargetsinteractionsfordepression
AT tianjunsheng novelnetworkpharmacologystrategytodecodemetabolicbiomarkersandtargetsinteractionsfordepression
AT qinxuemei novelnetworkpharmacologystrategytodecodemetabolicbiomarkersandtargetsinteractionsfordepression